Literature DB >> 22594507

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.

Marine L Andersson1, Erik Eliasson, Jonatan D Lindh.   

Abstract

BACKGROUND: Simvastatin interacts with warfarin, but the strength of the interaction varies between individual patients, indicating a genetic predisposition. PATIENTS &
METHODS: The influence of the CYP2C9*2 and CYP2C9*3 polymorphisms on the interaction between simvastatin and warfarin was analyzed in data from 1132 patients.
RESULTS: Simvastatin use reduced warfarin dose requirements by 29% in carriers of the CYP2C9*3 allele, compared with 5% in noncarriers. A regression model showed a significant influence of CYP2C9*3 on the drug-drug interaction, predicting a warfarin dose reduction of 25% in CYP2C9*3 heterozygotes and 43% in CYP2C9*3 homozygotes.
CONCLUSION: Our data indicate that the CYP2C9*3 polymorphism predisposes for a pharmacologic interaction between warfarin and simvastatin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22594507     DOI: 10.2217/pgs.12.40

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  7 in total

1.  Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Authors:  Sandhya Devarajan; Irene Moon; Ming-Fen Ho; Nicholas B Larson; Drew R Neavin; Ann M Moyer; John L Black; Suzette J Bielinski; Steven E Scherer; Liewei Wang; Richard M Weinshilboum; Joel M Reid
Journal:  Drug Metab Dispos       Date:  2019-02-11       Impact factor: 3.922

2.  The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study.

Authors:  Marine L Andersson; Buster Mannheimer; Jonatan D Lindh
Journal:  Eur J Clin Pharmacol       Date:  2019-06-14       Impact factor: 2.953

Review 3.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

Review 4.  Drug Interactions Affecting Oral Anticoagulant Use.

Authors:  Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-05-27

5.  Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

Authors:  Kuntheavy Ing Lorenzini; Youssef Daali; Pierre Fontana; Jules Desmeules; Caroline Samer
Journal:  Front Pharmacol       Date:  2016-12-19       Impact factor: 5.810

6.  Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study.

Authors:  R M Turner; E M de Koning; V Fontana; A Thompson; M Pirmohamed
Journal:  BMC Med       Date:  2020-11-25       Impact factor: 8.775

Review 7.  Drug-drug-gene interactions and adverse drug reactions.

Authors:  Mustafa Adnan Malki; Ewan Robert Pearson
Journal:  Pharmacogenomics J       Date:  2019-12-03       Impact factor: 3.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.